Our CNS pipeline includes six product candidates, including five clinical-stage investigational agents belonging to a new class of drugs known as pherines, in addition to AV-101, an oral antagonist of the glycine site of the N-methyl-D-aspartate receptor (NMDAR). Each of our drug candidates has a differentiated potential mechanism of action (or MOA), has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets.